HRP20240551T1 - Kombinacija regorafeniba i nivolumaba za liječenje raka - Google Patents

Kombinacija regorafeniba i nivolumaba za liječenje raka Download PDF

Info

Publication number
HRP20240551T1
HRP20240551T1 HRP20240551TT HRP20240551T HRP20240551T1 HR P20240551 T1 HRP20240551 T1 HR P20240551T1 HR P20240551T T HRP20240551T T HR P20240551TT HR P20240551 T HRP20240551 T HR P20240551T HR P20240551 T1 HRP20240551 T1 HR P20240551T1
Authority
HR
Croatia
Prior art keywords
combination
treatment
combination according
nivolumab
regorafenib
Prior art date
Application number
HRP20240551TT
Other languages
English (en)
Croatian (hr)
Inventor
Sabine HOFF
Lars RÖSE
Dieter Zopf
Fabian Kiessling
Wiltrud LEDERLE
Dennis DOLESCHEL
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of HRP20240551T1 publication Critical patent/HRP20240551T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
HRP20240551TT 2017-06-02 2018-05-25 Kombinacija regorafeniba i nivolumaba za liječenje raka HRP20240551T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17174169 2017-06-02
EP18725258.0A EP3630112B9 (en) 2017-06-02 2018-05-25 Combination of regorafenib and nivolumab for treating cancer
PCT/EP2018/063785 WO2018219807A1 (en) 2017-06-02 2018-05-25 Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
HRP20240551T1 true HRP20240551T1 (hr) 2024-07-05

Family

ID=58992733

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20240551TT HRP20240551T1 (hr) 2017-06-02 2018-05-25 Kombinacija regorafeniba i nivolumaba za liječenje raka

Country Status (22)

Country Link
US (4) US11951166B2 (enExample)
EP (2) EP3630112B9 (enExample)
JP (3) JP7303122B2 (enExample)
KR (2) KR102673422B1 (enExample)
CN (3) CN117582495A (enExample)
AU (2) AU2018276273B2 (enExample)
BR (1) BR112019025478A8 (enExample)
CA (2) CA3065125C (enExample)
DK (1) DK3630112T3 (enExample)
ES (1) ES2978337T3 (enExample)
FI (1) FI3630112T3 (enExample)
HR (1) HRP20240551T1 (enExample)
HU (1) HUE066487T2 (enExample)
IL (2) IL270948B2 (enExample)
LT (1) LT3630112T (enExample)
MX (1) MX2023001721A (enExample)
PE (2) PE20200859A1 (enExample)
PL (1) PL3630112T3 (enExample)
PT (1) PT3630112T (enExample)
RS (1) RS65488B9 (enExample)
SI (1) SI3630112T1 (enExample)
WO (1) WO2018219807A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3630112T3 (da) * 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
CN111001004A (zh) * 2019-10-08 2020-04-14 广州医科大学附属第二医院 一种治疗肝癌的药物组合及其应用
TW202539722A (zh) * 2023-12-01 2025-10-16 耶魯大學 治療癌症的組合物和方法
WO2026024670A1 (en) * 2024-07-23 2026-01-29 Lantern Pharma Inc. Treating triple negative breast cancer (tnbc) with combinations of immunotherapy and acylfulvenes

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
CA2628881A1 (en) 2005-11-10 2007-05-18 Bayer Healthcare Ag Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35006A (es) * 2012-09-06 2014-03-31 Bayer Healthcare Llc Composición farmacéutica recubierta que contiene regorafenib
WO2014048881A1 (en) * 2012-09-25 2014-04-03 Bayer Pharma Aktiengesellschaft Combination of regorafenib and acetylsalicylic acid for treating cancer
JP5653489B1 (ja) 2013-07-24 2015-01-14 三菱エンジニアリングプラスチックス株式会社 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法
SI3102605T1 (sl) 2014-02-04 2019-04-30 Pfizer Inc. Kombinacija PD-1 antagonista in VEGFR inhibitorja za zdravljenje raka
US20170165364A1 (en) 2014-02-21 2017-06-15 Idac Theranostics, Inc. Therapeutic agent for solid cancer
MX2017000546A (es) 2014-07-15 2017-03-08 Genentech Inc Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek.
CN114099686B (zh) 2014-07-15 2024-04-16 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
US10392444B2 (en) * 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
US20170231929A1 (en) * 2014-08-19 2017-08-17 National University Corporation Okayama University Method for enhancing immune cell function and method for assessing immune cell multifunctionality
KR20170066546A (ko) * 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EP4098278A1 (en) 2014-11-13 2022-12-07 The Johns Hopkins University Checkpoint blockade and microsatellite instability
WO2016173959A1 (en) * 2015-04-28 2016-11-03 Bayer Pharma Aktiengesellschaft Regorafenib for treating colorectal cancer
US20190022092A1 (en) 2015-09-15 2019-01-24 Acerta Pharma B.V. Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
US20190183972A1 (en) 2016-06-03 2019-06-20 Imclone Llc Combination of ramucirumab and pembrolizumab for the treatment of certain cancers
US10251888B2 (en) 2016-06-13 2019-04-09 Chemocentryx, Inc. Method of treating pancreatic cancer
DK3630112T3 (da) 2017-06-02 2024-04-22 Bayer Healthcare Llc Kombination af regorafenib og nivolumab til behandling af cancer
CR20190550A (es) * 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso

Also Published As

Publication number Publication date
IL270948B2 (en) 2025-07-01
EP3630112A1 (en) 2020-04-08
JP2022169780A (ja) 2022-11-09
CN117899212A (zh) 2024-04-19
WO2018219807A1 (en) 2018-12-06
BR112019025478A8 (pt) 2022-12-06
EP4342542A3 (en) 2024-06-05
CA3065125A1 (en) 2018-12-06
ES2978337T3 (es) 2024-09-10
RU2019143599A3 (enExample) 2021-09-10
LT3630112T (lt) 2024-05-10
KR20240091188A (ko) 2024-06-21
EP4342542A2 (en) 2024-03-27
MX2023001721A (es) 2023-02-22
PT3630112T (pt) 2024-04-23
KR20200011971A (ko) 2020-02-04
SI3630112T1 (sl) 2024-06-28
US20200188372A1 (en) 2020-06-18
PL3630112T3 (pl) 2024-07-01
JP7475402B2 (ja) 2024-04-26
EP3630112B9 (en) 2024-06-26
US11517622B2 (en) 2022-12-06
EP3630112B1 (en) 2024-01-31
AU2018276273B2 (en) 2023-12-21
PE20242220A1 (es) 2024-11-19
US11951166B2 (en) 2024-04-09
CA3244313A1 (en) 2025-06-13
RS65488B9 (sr) 2024-09-30
DK3630112T3 (da) 2024-04-22
AU2023282197B2 (en) 2025-06-26
HUE066487T2 (hu) 2024-08-28
IL270948B1 (en) 2025-03-01
RU2019143599A (ru) 2021-07-09
JP7303122B2 (ja) 2023-07-04
US20200179354A1 (en) 2020-06-11
JP2020521786A (ja) 2020-07-27
IL270948A (en) 2020-01-30
AU2018276273A1 (en) 2019-12-12
AU2023282197A1 (en) 2024-01-04
KR102843438B1 (ko) 2025-08-06
CN110662540B (zh) 2024-01-26
FI3630112T3 (fi) 2024-05-02
KR102673422B1 (ko) 2024-06-07
US20220133888A1 (en) 2022-05-05
RS65488B1 (sr) 2024-05-31
CN110662540A (zh) 2020-01-07
JP7806119B2 (ja) 2026-01-26
IL317015A (en) 2025-01-01
US20200155674A1 (en) 2020-05-21
CA3065125C (en) 2025-06-10
CN117582495A (zh) 2024-02-23
BR112019025478A2 (pt) 2020-06-23
JP2024096905A (ja) 2024-07-17
PE20200859A1 (es) 2020-08-25

Similar Documents

Publication Publication Date Title
HRP20201681T1 (hr) Inhibitor aurora a kinaze
JP2015529234A5 (enExample)
HRP20200180T1 (hr) Derivati (aza-)izokinolinona
HRP20231163T1 (hr) Prolijekovi glutaminskih analoga
MX2021002321A (es) Nuevos metodos.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
EA201892395A1 (ru) Лекарственные составы ингибитора lsd1
PH12017500479B1 (en) Liquid inhalation formulation comprising rpl554
JP2016106150A5 (enExample)
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
JP2015511609A5 (enExample)
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
RU2016141570A (ru) Комбинации ингибитора fgfr и ингибитора igf1r
EP3325080A4 (en) METHOD FOR BETTER ADMINISTRATION OF AGENTS AGAINST TUMORS
JP2015038135A5 (enExample)
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
JP2022169780A5 (enExample)
FI3630112T3 (fi) Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
PH12017501829A1 (en) Pharmaceutical formulations
MX2017013950A (es) Polvos de zolmitriptán para suministro pulmonar.
JP2020521786A5 (enExample)
MX2018013475A (es) Acido carboxilico para tratar/prevenir congestion nasal.
MX2022007438A (es) Combinacion de inhibidores de ahr.
JP2016537344A5 (enExample)